Odonate Therapeutics Stock Net Income
| ODTC Stock | USD 50,000 0.00 0.00% |
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Odonate Therapeutics, as well as the relationship between them.
Odonate Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Odonate Therapeutics' valuation are provided below:Odonate Therapeutics does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Odonate |
Odonate Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Odonate Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Odonate Therapeutics.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Odonate Therapeutics on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Odonate Therapeutics or generate 0.0% return on investment in Odonate Therapeutics over 90 days. Odonate Therapeutics is related to or competes with JD Health, and TuHURA Biosciences. Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer More
Odonate Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Odonate Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Odonate Therapeutics upside and downside potential and time the market with a certain degree of confidence.
Odonate Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Odonate Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Odonate Therapeutics' standard deviation. In reality, there are many statistical measures that can use Odonate Therapeutics historical prices to predict the future Odonate Therapeutics' volatility.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Odonate Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Odonate Therapeutics Backtested Returns
We have found three technical indicators for Odonate Therapeutics, which you can use to evaluate the volatility of the company. The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Odonate Therapeutics are completely uncorrelated.
Auto-correlation | 0.00 |
No correlation between past and present
Odonate Therapeutics has no correlation between past and present. Overlapping area represents the amount of predictability between Odonate Therapeutics time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Odonate Therapeutics price movement. The serial correlation of 0.0 indicates that just 0.0% of current Odonate Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Odonate Therapeutics reported net income of (126.35 Million). This is 109.89% lower than that of the Financial Services sector and significantly lower than that of the Shell Companies industry. The net income for all United States stocks is 122.13% higher than that of the company.
Odonate Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Odonate Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Odonate Therapeutics could also be used in its relative valuation, which is a method of valuing Odonate Therapeutics by comparing valuation metrics of similar companies.Odonate Therapeutics is currently under evaluation in net income category among its peers.
Odonate Fundamentals
| Return On Equity | -0.86 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | (26.67 M) | |||
| Shares Outstanding | 38.49 M | |||
| Shares Owned By Insiders | 3.61 % | |||
| Shares Owned By Institutions | 9.60 % | |||
| Number Of Shares Shorted | 379.63 K | |||
| Price To Book | 0.89 X | |||
| EBITDA | (125.91 M) | |||
| Net Income | (126.35 M) | |||
| Cash And Equivalents | 95.03 M | |||
| Cash Per Share | 2.47 X | |||
| Total Debt | 4.85 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 3.29 X | |||
| Book Value Per Share | 1.85 X | |||
| Cash Flow From Operations | (113.13 M) | |||
| Short Ratio | 0.59 X | |||
| Earnings Per Share | (2.71) X | |||
| Target Price | 4.0 | |||
| Number Of Employees | 137 | |||
| Beta | 0.0342 | |||
| Market Capitalization | 69.28 M | |||
| Total Asset | 167.89 M | |||
| Z Score | 8.4 | |||
| Net Asset | 167.89 M |
About Odonate Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Odonate Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Odonate Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Odonate Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Odonate Pink Sheet
Odonate Therapeutics financial ratios help investors to determine whether Odonate Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Odonate with respect to the benefits of owning Odonate Therapeutics security.